Fertility Sparing Treatments in Endometrial Cancer Patients: The Potential Role of the New Molecular Classification.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
12 Nov 2021
Historique:
received: 20 10 2021
accepted: 10 11 2021
entrez: 27 11 2021
pubmed: 28 11 2021
medline: 21 12 2021
Statut: epublish

Résumé

Endometrial cancer is the most frequent gynecological malignancy, and, although epidemiologically it mainly affects advanced age women, it can also affect young patients who want children and who have not yet completed their procreative project. Fertility sparing treatments are the subject of many studies and research in continuous evolution, and represent a light of hope for young cancer patients who find themselves having to face an oncological path before fulfilling their desire for motherhood. The advances in molecular biology and the more precise clinical and prognostic classification of endometrial cancer based on the 2013 The Cancer Genome Atlas classification allow for the selection of patients who can be submitted to fertility sparing treatments with increasing oncological safety. It would also be possible to predict the response to hormonal treatment by investigating the state of the genes of the mismatch repair.

Identifiants

pubmed: 34830129
pii: ijms222212248
doi: 10.3390/ijms222212248
pmc: PMC8625356
pii:
doi:

Substances chimiques

Progestins 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Eur J Obstet Gynecol Reprod Biol. 2019 Sep;240:220-225
pubmed: 31326637
Gynecol Oncol. 2018 Sep;150(3):398-405
pubmed: 30126588
Gynecol Oncol. 2014 Apr;133(1):23-7
pubmed: 24680587
Genes (Basel). 2014 Jun 27;5(3):497-507
pubmed: 24978665
JAMA. 2011 Jun 8;305(22):2304-10
pubmed: 21642682
Carcinogenesis. 2019 Jul 4;40(5):611-623
pubmed: 30850842
Genes (Basel). 2018 Mar 29;9(4):
pubmed: 29596364
Histopathology. 2020 Jan;76(1):52-63
pubmed: 31846532
Gynecol Oncol. 1983 Feb;15(1):10-7
pubmed: 6822361
Front Oncol. 2021 Sep 01;11:612450
pubmed: 34540651
Gynecol Oncol. 2001 Nov;83(2):388-93
pubmed: 11606102
Cancer. 2006 Feb 15;106(4):804-11
pubmed: 16400640
Minerva Med. 2021 Feb;112(1):55-69
pubmed: 33205638
J Endocrinol Invest. 2020 Feb;43(2):257-265
pubmed: 31784912
Gynecol Oncol Res Pract. 2016 Feb 09;3:1
pubmed: 27231573
Obstet Gynecol Sci. 2020 Jul;63(4):417-431
pubmed: 32689770
J Clin Oncol. 1999 Jun;17(6):1736-44
pubmed: 10561210
Jpn J Clin Oncol. 2012 Dec;42(12):1215-8
pubmed: 23071290
Eur J Cancer. 2013 Mar;49(4):868-74
pubmed: 23072814
Int J Gynecol Cancer. 2016 Jan;26(1):2-30
pubmed: 26645990
Obstet Gynecol. 1998 Mar;91(3):349-54
pubmed: 9491858
Fertil Steril. 2014 Mar;101(3):785-94
pubmed: 24388202
Int J Gynecol Cancer. 2021 Mar;31(3):345-351
pubmed: 32565487
J Gynecol Oncol. 2019 May;30(3):e45
pubmed: 30887762
J Mol Diagn. 2021 Feb;23(2):242-252
pubmed: 33259954
Cancer. 2012 Mar 15;118(6):1710-7
pubmed: 21887678
Acta Obstet Gynecol Scand. 2019 Sep;98(9):1086-1099
pubmed: 30793281
Gynecol Oncol. 2004 Oct;95(1):133-8
pubmed: 15385122
JAMA. 2017 Mar 28;317(12):1224-1233
pubmed: 28350928
Int J Gynecol Cancer. 2020 Nov;30(11):1811-1823
pubmed: 32381512
Front Oncol. 2021 Sep 22;11:724886
pubmed: 34631553
Gynecol Oncol. 2014 Aug;134(2):426-7
pubmed: 24952365
J Assist Reprod Genet. 2014 Sep;31(9):1189-94
pubmed: 25106937
Int J Gynecol Cancer. 2019 May;29(4):699-704
pubmed: 30826750
J Gynecol Oncol. 2018 May;29(3):e35
pubmed: 29533020
Ann Surg Oncol. 2017 May;24(5):1322-1329
pubmed: 27896507
J Clin Oncol. 2009 Nov 10;27(32):5331-6
pubmed: 19805679
Gynecol Oncol. 2009 Apr;113(1):105-8
pubmed: 19167049
J Natl Compr Canc Netw. 2021 Aug 01;19(8):888-895
pubmed: 34416706
Am J Surg Pathol. 2009 Dec;33(12):1869-77
pubmed: 19898223
Am J Obstet Gynecol. 2021 Apr;224(4):370.e1-370.e13
pubmed: 33039397
Int J Mol Sci. 2021 Mar 19;22(6):
pubmed: 33808791
Front Cell Infect Microbiol. 2012 Jul 05;2:93
pubmed: 22919684
Acta Biomed. 2019 Dec 23;90(4):405-410
pubmed: 31910163
Ecancermedicalscience. 2020 May 06;14:1035
pubmed: 32419847
Gynecol Oncol. 2014 May;133(2):197-204
pubmed: 24556061
Contemp Clin Trials. 2014 Sep;39(1):14-21
pubmed: 24999075
Surg Pathol Clin. 2016 Sep;9(3):405-26
pubmed: 27523969
Int J Gynecol Pathol. 2019 Jan;38(1):44-51
pubmed: 29210800
Gynecol Oncol. 2019 Jun;153(3):487-495
pubmed: 30922603
Expert Rev Anticancer Ther. 2006 Jan;6(1):27-32
pubmed: 16375641
Obstet Gynecol. 2007 Mar;109(3):655-62
pubmed: 17329517
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
Healthcare (Basel). 2021 Jul 30;9(8):
pubmed: 34442102
J Minim Invasive Gynecol. 2018 Jul - Aug;25(5):872-877
pubmed: 29339300
Int J Gynecol Cancer. 2016 Jan;26(1):35-42
pubmed: 26658364
Int J Mol Sci. 2020 Sep 29;21(19):
pubmed: 33003368
Obstet Gynecol. 2015 Jan;125(1):89-98
pubmed: 25560109
Gynecol Oncol. 2015 Dec;139(3):424-8
pubmed: 26428941
Gynecol Oncol. 2018 Sep;150(3):569-580
pubmed: 29843906
Future Oncol. 2019 Apr;15(12):1335-1346
pubmed: 30887833
Ecancermedicalscience. 2015 Feb 03;9:505
pubmed: 25729418
Gynecol Oncol. 2013 Sep;130(3):470-3
pubmed: 23822890
Lancet Oncol. 2010 Aug;11(8):763-71
pubmed: 20638901
Mod Pathol. 2017 Jul;30(7):1032-1041
pubmed: 28281553
Am J Surg Pathol. 2018 May;42(5):561-568
pubmed: 29505428
Cancer Lett. 2001 Jun 10;167(1):39-48
pubmed: 11323097
Am J Obstet Gynecol. 2021 Apr;224(4):408-410
pubmed: 33385345
Int J Gynecol Cancer. 2015 Sep;25(7):1258-65
pubmed: 26186070
Taiwan J Obstet Gynecol. 2011 Mar;50(1):62-6
pubmed: 21482377
Gynecol Oncol. 2012 May;125(2):477-82
pubmed: 22245711
Clin Obstet Gynecol. 2018 Sep;61(3):454-462
pubmed: 30047928
Am J Obstet Gynecol. 2012 Oct;207(4):266.e1-12
pubmed: 23021687
Eur J Cancer. 2012 Sep;48(14):2155-62
pubmed: 22503396
Int J Gynecol Cancer. 2018 Mar;28(3):529-538
pubmed: 29369119
Gynecol Oncol. 2021 Jun;161(3):795-801
pubmed: 33812697
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
J Gynecol Oncol. 2019 Jul;30(4):e61
pubmed: 31074242
Gynecol Oncol. 2017 Nov;147(2):381-387
pubmed: 28822557
Arch Gynecol Obstet. 2019 Jun;299(6):1673-1682
pubmed: 30953185

Auteurs

Anna Franca Cavaliere (AF)

Azienda USL Toscana Centro, Gynecology and Obstetric Department, Santo Stefano Hospital, 59100 Prato, Italy.

Federica Perelli (F)

Azienda USL Toscana Centro, Gynecology and Obstetric Department, Santa Maria Annunziata Hospital, 50012 Florence, Italy.

Simona Zaami (S)

Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Viale Regina Elena 336, 00161 Rome, Italy.

Marco D'Indinosante (M)

Azienda USL Toscana Centro, Gynecology and Obstetric Department, Santo Stefano Hospital, 59100 Prato, Italy.

Irene Turrini (I)

Azienda USL Toscana Centro, Gynecology and Obstetric Department, Santo Stefano Hospital, 59100 Prato, Italy.

Marco Giusti (M)

Azienda USL Toscana Centro, Gynecology and Obstetric Department, Santa Maria Annunziata Hospital, 50012 Florence, Italy.

Giuseppe Gullo (G)

Azienda Ospedaliera Ospedali Riuniti (AOOR) Villa Sofia Cervello, IVF Public Center, University of Palermo, 90100 Palermo, Italy.

Giuseppe Vizzielli (G)

Clinic of Obstetrics and Gynecology, Dipartimento di Area Medica (DAME), University Hospital of Udine, University of Udine, 33100 Udine, Italy.

Alberto Mattei (A)

Azienda USL Toscana Centro, Gynecology and Obstetric Department, Santa Maria Annunziata Hospital, 50012 Florence, Italy.

Giovanni Scambia (G)

Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00168 Rome, Italy.

Annalisa Vidiri (A)

Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00168 Rome, Italy.

Fabrizio Signore (F)

Obstetrics and Gynecology Department, Unità Sanitaria Locale (USL) Roma 2, Sant'Eugenio Hospital, 00144 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH